Aptorum Group Ltd Class A (NASDAQ:APM) — Market Cap & Net Worth
Market Cap & Net Worth: Aptorum Group Ltd Class A (APM)
Aptorum Group Ltd Class A (NASDAQ:APM) has a market capitalization of $5.52 Million ($5.52 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28392 globally and #5763 in its home market, demonstrating a -22.32% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aptorum Group Ltd Class A's stock price $0.87 by its total outstanding shares 6346823 (6.35 Million). Review APM total liabilities to assess the company's total debt and financial obligations.
Aptorum Group Ltd Class A Market Cap History: 2018 to 2026
Aptorum Group Ltd Class A's market capitalization history from 2018 to 2026. Data shows change from $963.45 Million to $5.52 Million (-49.37% CAGR).
Index Memberships
Aptorum Group Ltd Class A is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #831 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #2656 of 3165 |
Weight: Aptorum Group Ltd Class A's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Aptorum Group Ltd Class A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aptorum Group Ltd Class A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
36.03x
Aptorum Group Ltd Class A's market cap is 36.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $963.45 Million | $383.45K | -$14.83 Million | 2512.58x | N/A |
| 2019 | $1.01 Billion | $535.17K | -$18.69 Million | 1879.73x | N/A |
| 2020 | $156.77 Million | $911.51K | $7.07 Million | 171.99x | 22.18x |
| 2021 | $95.20 Million | $1.54 Million | -$25.05 Million | 61.74x | N/A |
| 2022 | $34.91 Million | $1.30 Million | -$9.80 Million | 26.94x | N/A |
| 2023 | $15.54 Million | $431.38K | -$2.83 Million | 36.03x | N/A |
Competitor Companies of APM by Market Capitalization
Companies near Aptorum Group Ltd Class A in the global market cap rankings as of June 18, 2026.
Key companies related to Aptorum Group Ltd Class A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Aptorum Group Ltd Class A Historical Marketcap From 2018 to 2026
Between 2018 and today, Aptorum Group Ltd Class A's market cap moved from $963.45 Million to $ 5.52 Million, with a yearly change of -49.37%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $5.52 Million | -17.92% |
| 2025 | $6.73 Million | -62.14% |
| 2024 | $17.77 Million | +14.35% |
| 2023 | $15.54 Million | -55.49% |
| 2022 | $34.91 Million | -63.33% |
| 2021 | $95.20 Million | -39.27% |
| 2020 | $156.77 Million | -84.42% |
| 2019 | $1.01 Billion | +4.41% |
| 2018 | $963.45 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Aptorum Group Ltd Class A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.52 Million USD |
| MoneyControl | $5.52 Million USD |
| MarketWatch | $5.52 Million USD |
| marketcap.company | $5.52 Million USD |
| Reuters | $5.52 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Aptorum Group Ltd Class A
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small mol… Read more